Aura Biosciences, INC Form 4 insider transactions

Aura Biosciences Director Jeremy Bender acquired 30,000 shares of common stock through an RSU award and was granted an option to purchase 60,000 shares.

Aura Biosciences reports a Form 4 filing detailing the acquisition of common stock by Conor Kilroy, Chief Legal Officer and Secretary.

Aura Biosciences reports that Chief Financial and Business Officer Anthony S. Gibney sold shares to cover tax withholding obligations upon vesting of restricted stock units.

Aura Biosciences Director Teresa Marie Bitetti acquired 15,000 restricted stock units and a stock option for 30,000 shares.

Aura Biosciences Director Sapna Srivastava acquired 15,000 restricted stock units and was granted 30,000 stock options.

Aura Biosciences Director Antony C. Mattessich acquired 15,000 shares of common stock and was granted 30,000 stock options.

Aura Biosciences reports on insider stock awards and option grants to Natalie C. Holles, including restricted stock units and performance-based restricted stock units.

Matrix Capital Management Company, LP and David E. Goel have reported a significant transaction involving Aura Biosciences, Inc. common stock.

Chief Legal Officer Conor Kilroy sold 11,738 shares of Aura Biosciences to satisfy tax withholding obligations.

Aura Biosciences, Inc. reported equity grants to Chief Legal Officer and Secretary Conor Kilroy, including 62,339 restricted stock units and options for 112,661 shares.

Aura Biosciences' Chief Financial and Business Officer, Anthony S. Gibney, was granted 71,245 restricted stock units and options to purchase 128,755 shares.

Aura Biosciences' Chief Technology Officer, Mark Plavsic, acquired 62,339 shares via restricted stock units and 112,661 stock options.

Aura Biosciences' Chief Medical Officer, Janet Jill Hopkins, received grants of 89,056 restricted stock units and 160,944 stock options.

Aura Biosciences' Senior Vice President of Finance, Amy Elazzouzi, increased her beneficial ownership through new equity awards, including restricted stock units and stock options.

Aura Biosciences' Senior VP of Finance, Amy Elazzouzi, sold 1,581 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Aura Biosciences' President and CEO, Elisabet de los Pinos, sold 16,928 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Aura Biosciences' Chief Medical Officer, Janet Jill Hopkins, sold 17,109 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Aura Biosciences' Senior VP of Finance, Amy Elazzouzi, sold 896 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Aura Biosciences CEO Elisabet de los Pinos sold 9,049 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Aura Biosciences' Chief Technology Officer, Mark Plavsic, sold 12,169 shares of common stock at $6.35 per share to cover tax withholding obligations related to restricted stock unit vesting.

Aura Biosciences' Senior VP of Finance, Amy Elazzouzi, exercised stock options and sold a portion of the acquired shares to cover costs.

Sapna Srivastava, a Director at Aura Biosciences, Inc., was granted 13,000 restricted stock units and 17,000 stock options on June 17, 2025, as part of the company's incentive plan.

Aura Biosciences Director David Michael Johnson has increased his beneficial ownership in the company through the acquisition of 13,000 restricted stock units and 17,000 stock options, as reported in a recent SEC Form 4 filing.

Aura Biosciences, Inc. Director Antony C. Mattessich was granted 13,000 Restricted Stock Units and 17,000 stock options on June 17, 2025, as part of the company's incentive plan.

Aura Biosciences, Inc.'s Chief Financial and Business Officer, Anthony S. Gibney, was granted 150,000 restricted stock units and 250,000 stock options, aligning his interests with the company's long-term performance.

Elisabet de los Pinos, President and CEO of Aura Biosciences, Inc., reported the exercise of stock options and related share dispositions, resulting in changes to her beneficial ownership.

Director David Michael Johnson reports purchasing 20,000 shares of Aura Biosciences and warrants for 5,000 shares in a recent transaction.

Anthony S. Gibney, CFO of Aura Biosciences, purchased shares and warrants in a public offering and sold shares to cover tax obligations.

Amy Elazzouzi, Senior Vice President of Finance at Aura Biosciences, sold 897 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Conor Kilroy, Chief Legal Officer and Secretary of Aura Biosciences, sold 7,162 shares of common stock on April 16, 2025, to cover tax withholding obligations related to vesting restricted stock units.